BofA raised the firm’s price target on NeoGenomics (NEO) to $11 from $6.50 and keeps a Neutral rating on the shares after “a solid quarter.” The firm views the quarterly update as “constructive,” but sees questions on the sustainability of the growth rate and the competitive position, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Reports Strong Revenue Growth Amid Rising Losses
- NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges
- Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target
- NeoGenomics price target raised to $14 from $12 at Leerink
- Balanced Outlook on NeoGenomics: Hold Rating Amid Growth Potential and Long-Term Skepticism